Company profile

MediLink Therapeutics (Suzhou) Co., Ltd.

Privately held: no public share price (Privately held venture-backed ADC biotech; no IPO or exchange listing found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.crunchbase.com/organization/medilink-therapeutics]) · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
YL202
Phase 3
EGFR + HER3Antibody–drug conjugate
Non-Small Cell Lung CancerHR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
YL201
Phase 2
B7-H3Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.